Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on May 27, 2015. The filing discloses the execution of new executive employment agreements and an amendment to an existing offer letter for key officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Christoph Westphal (CEO/Chairman): Annual base salary of $459,000; target annual bonus of 50% of base salary.
- John McCabe (VP Finance/Treasurer): Annual base salary of $270,300; target annual bonus of 30% of base salary.
- Marina Hahn (President Consumer): Compensation terms amended regarding severance and equity acceleration; specific salary figures not restated in this filing.
Material Changes
The primary material change is the formalization of compensation and severance packages for three executives effective May 27, 2015:
- Westphal Agreement: Establishes 12 months of salary continuation for termination without Cause or resignation for Good Reason. In the event of a Change in Control, severance includes 12 months of salary plus the target bonus.
- McCabe Agreement: Establishes 6 months of salary continuation and COBRA premium coverage for termination without Cause or resignation for Good Reason. In the event of a Change in Control, the executive receives 100% acceleration of unvested equity awards.
- Hahn Amendment: Modifies the September 2014 offer letter to provide up to 9 months of COBRA premium coverage for termination without Cause or resignation for Good Reason. In the event of a Change in Control, the executive receives 100% acceleration of unvested equity awards.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of general business risks. The primary contingency disclosed relates to potential future severance liabilities triggered by termination without Cause, resignation for Good Reason, or a Change in Control.
Investor Verification Checklist
- Verify the exact definitions of "Cause," "Good Reason," and "Change in Control" in the full text of Exhibits 10.1, 10.2, and 10.3.
- Confirm the total outstanding unvested equity awards held by John McCabe and Marina Hahn to assess the potential cost of acceleration.
- Review the Company's cash position to determine the ability to fund potential severance payments (up to 12 months of CEO salary plus bonus).
- Check subsequent filings for any changes to the Board's discretion regarding performance goal attainment for bonuses.